These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

66 related items for PubMed ID: 9207936

  • 1. Structure-activity relationships of N-hydroxyurea 5-lipoxygenase inhibitors.
    Stewart AO, Bhatia PA, Martin JG, Summers JB, Rodriques KE, Martin MB, Holms JH, Moore JL, Craig RA, Kolasa T, Ratajczyk JD, Mazdiyasni H, Kerdesky FA, DeNinno SL, Maki RG, Bouska JB, Young PR, Lanni C, Bell RL, Carter GW, Brooks CD.
    J Med Chem; 1997 Jun 20; 40(13):1955-68. PubMed ID: 9207936
    [Abstract] [Full Text] [Related]

  • 2. (R)-(+)-N-[3-[5-[(4-fluorophenyl)methyl]-2-thienyl]-1-methyl- 2-propynyl]-N-hydroxyurea (ABT-761), a second-generation 5-lipoxygenase inhibitor.
    Brooks CD, Stewart AO, Basha A, Bhatia P, Ratajczyk JD, Martin JG, Craig RA, Kolasa T, Bouska JB, Lanni C.
    J Med Chem; 1995 Nov 24; 38(24):4768-75. PubMed ID: 7490726
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.
    Adams JL, Garigipati RS, Sorenson M, Schmidt SJ, Brian WR, Newton JF, Tyrrell KA, Garver E, Yodis LA, Chabot-Fletcher M, Tzimas M, Webb EF, Breton JJ, Griswold DE.
    J Med Chem; 1996 Dec 20; 39(26):5035-46. PubMed ID: 8978834
    [Abstract] [Full Text] [Related]

  • 6. Identification of the human liver cytochrome P450 enzymes involved in the in vitro metabolism of a novel 5-lipoxygenase inhibitor.
    Machinist JM, Mayer MD, Roberts EM, Surber BW, Rodrigues AD.
    Drug Metab Dispos; 1998 Oct 20; 26(10):970-6. PubMed ID: 9763401
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of 5-lipoxygenase: development of hydroxamic acids and hydroxyureas as potential therapeutic agents.
    Salmon JA, Jackson WP, Garland LG.
    Adv Prostaglandin Thromboxane Leukot Res; 1991 Oct 20; 21A():109-12. PubMed ID: 1847758
    [No Abstract] [Full Text] [Related]

  • 8. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
    Devadas B, Freeman SK, Zupec ME, Lu HF, Nagarajan SR, Kishore NS, Lodge JK, Kuneman DW, McWherter CA, Vinjamoori DV, Getman DP, Gordon JI, Sikorski JA.
    J Med Chem; 1997 Aug 01; 40(16):2609-25. PubMed ID: 9258368
    [Abstract] [Full Text] [Related]

  • 9. Substituted coumarins as potent 5-lipoxygenase inhibitors.
    Grimm EL, Brideau C, Chauret N, Chan CC, Delorme D, Ducharme Y, Ethier D, Falgueyret JP, Friesen RW, Guay J, Hamel P, Riendeau D, Soucy-Breau C, Tagari P, Girard Y.
    Bioorg Med Chem Lett; 2006 May 01; 16(9):2528-31. PubMed ID: 16464579
    [Abstract] [Full Text] [Related]

  • 10. Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity.
    Lewis TA, Young MA, Arrington MP, Bayless L, Cai X, Collart P, Eckman JB, Ellis JL, Ene DG, Libertine L, Nicolas JM, Scannell RT, Wels BF, Wenberg K, Wypij DM.
    Bioorg Med Chem Lett; 2004 Nov 15; 14(22):5591-4. PubMed ID: 15482930
    [Abstract] [Full Text] [Related]

  • 11. Structure and activity relationships leading to the discovery of ICI D2138, a selective, potent and orally active inhibitor of 5-lipoxygenase.
    Crawley GC, Bird TG, Bruneau P, Dowell RI, Edwards PN, Foster SJ, Girodeau JM, McMillan RM, Walker ER, Waterson D.
    J Lipid Mediat; 1993 Nov 15; 6(1-3):249-57. PubMed ID: 8395247
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers.
    Wong SL, Drajesk J, Chang M, Lanni C, Witt G, Hansen R, Awni WM.
    Clin Pharmacol Ther; 1998 Mar 15; 63(3):324-31. PubMed ID: 9542476
    [Abstract] [Full Text] [Related]

  • 13. 5-Lipoxygenase inhibition by N-hydroxycarbamates in dual-function compounds.
    Lewis TA, Bayless L, DiPesa AJ, Eckman JB, Gillard M, Libertine L, Scannell RT, Wypij DM, Young MA.
    Bioorg Med Chem Lett; 2005 Feb 15; 15(4):1083-5. PubMed ID: 15686917
    [Abstract] [Full Text] [Related]

  • 14. Improving the in vivo duration of 5-lipoxygenase inhibitors: application of an in vitro glucuronosyltransferase assay.
    Bouska JJ, Bell RL, Goodfellow CL, Stewart AO, Brooks CD, Carter GW.
    Drug Metab Dispos; 1997 Sep 15; 25(9):1032-8. PubMed ID: 9311617
    [Abstract] [Full Text] [Related]

  • 15. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR, Hamby JM, Boschelli DH, Wu Z, Kraker AJ, Amar AM, Hartl BG, Shen C, Klohs WD, Steinkampf RW, Driscoll DL, Nelson JM, Elliott WL, Roberts BJ, Stoner CL, Vincent PW, Dykes DJ, Panek RL, Lu GH, Major TC, Dahring TK, Hallak H, Bradford LA, Showalter HD, Doherty AM.
    J Med Chem; 1998 Aug 13; 41(17):3276-92. PubMed ID: 9703473
    [Abstract] [Full Text] [Related]

  • 16. ABT-761 (Abbott).
    Reid JJ.
    Curr Opin Investig Drugs; 2001 Jan 13; 2(1):68-71. PubMed ID: 11527015
    [Abstract] [Full Text] [Related]

  • 17. New cyclooxygenase-2/5-lipoxygenase inhibitors. 3. 7-tert-butyl-2, 3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: variations at the 5 position.
    Janusz JM, Young PA, Ridgeway JM, Scherz MW, Enzweiler K, Wu LI, Gan L, Chen J, Kellstein DE, Green SA, Tulich JL, Rosario-Jansen T, Magrisso IJ, Wehmeyer KR, Kuhlenbeck DL, Eichhold TH, Dobson RL.
    J Med Chem; 1998 Aug 27; 41(18):3515-29. PubMed ID: 9719605
    [Abstract] [Full Text] [Related]

  • 18. In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase.
    Albrecht W, Unger A, Nussler AK, Laufer S.
    Drug Metab Dispos; 2008 May 27; 36(5):894-903. PubMed ID: 18268076
    [Abstract] [Full Text] [Related]

  • 19. Studies of synergism between inhibitors of the 5-lipoxygenase pathway.
    Bach MK, Brashler JR.
    Adv Prostaglandin Thromboxane Leukot Res; 1989 May 27; 19():511-4. PubMed ID: 2526529
    [No Abstract] [Full Text] [Related]

  • 20. Synthesis and biological evaluation of acyclic triaryl (Z)-olefins possessing a 3,5-di-tert-butyl-4-hydroxyphenyl pharmacophore: dual inhibitors of cyclooxygenases and lipoxygenases.
    Moreau A, Rao PN, Knaus EE.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5340-50. PubMed ID: 16677817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.